mm-111
mAbexperimentalMulti-specific
Clinical trial activity
4 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2009 (NCT00911898)
Timeline
Indications
Mechanism of action
ERBB3 inhibitor
- ErbB-2/ErbB-3 heterodimerINHIBITOR
ErbB-2/ErbB-3 heterodimer inhibitor
ERBB2 inhibitor
Chemistry & pharmacology
- Inorganic
- No
- Polymer
- No
- Multi-specific
- Yes
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4297556 ↗
Also known as
- mm-111
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01774851 | Phase 2 | Jan 1, 2013 | Merrimack Pharmaceuticals |
| NCT01304784 | Phase 1 | Jan 1, 2011 | Baylor University, Merrimack Pharmaceuticals |
| NCT01097460 | Phase 1 | Apr 1, 2010 | Harvard University, Merrimack Pharmaceuticals |
| NCT00911898 | Phase 1 | Jun 1, 2009 | Merrimack Pharmaceuticals, The START Center for Cancer Care |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Merrimack Pharmaceuticals | For profit | 4 | 4 | 2 | 2009 |
| Baylor University | Academic/Hospital | 1 | 0 | 1 | 2011 |
| Harvard University | Academic/Hospital | 1 | 0 | 1 | 2010 |
| The START Center for Cancer Care | Academic/Hospital | 1 | 0 | 1 | 2009 |
4 organizations
Page 1 / 1